Data shows Latino and Black people make up nearly 30% of the Bay Area population but only about 10% of active medical ...

Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.

RBC Capital analyst Brian Abrahams maintained a Hold rating on 89bio (ETNB – Research Report) yesterday and set a price target of $12.00.

Prospects for Gilead Sciences' Trodelvy in hormone receptor ... of the University of California San Francisco Comprehensive Cancer Centre. "Nearly all patients with HR+/HER2- metastatic breast ...

Breckenridge spirits have been awarded 6 Double Golds at the San Francisco World Spirits Competition ... access to their most valuable assets when making both current... Gilead Sciences, Inc. today ...

On September 30th, 1996, Roche entered into a collaboration agreement with Gilead Sciences ... Nutley was moved to Genentech’s facility in San Francisco. Genentech strengthens Roche’s access ...

Gilead’s layoffs include 72 employees at its Seattle location, which will close. Kite will shut down its Philadelphia ...

Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Heal ...

Headquartered in Foster City, California, Gilead Sciences, Inc. (GILD) is a prominent biopharmaceutical company with a market ...

Headquartered in Foster City, California, Gilead Sciences, Inc. (GILD) is a prominent biopharmaceutical company with a market cap of $114.2 billion. Gilead specializes in developing and ...

Revenue: US$7.55b (up 7.0% from 3Q 2023). Net income: US$1.25b (down 43% from 3Q 2023). Profit margin: 17% (down from 31% in 3Q 2023). EPS: US$1.01 (down from US$1.75 in 3Q 2023). Revenue exceeded ...